We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pozen Files NDA for Trexima After Abandoning MT 100 Migraine Drug
Pozen Files NDA for Trexima After Abandoning MT 100 Migraine Drug
August 12, 2005
Pozen abandoned its experimental migraine drug MT 100 Aug. 5, one day after an FDA advisory panel rejected the product based on its safety risks.